Top Markets
Coin of the day
Sensorion SA Sensorion SA

Sensorion SA

ALSEN
주식 순위 #13334
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
주가
$0.30840035
시가총액
$94.37M
변동 (1일)
0.00%
변동 (1년)
-34.60%
국가
FR
거래 Sensorion SA (ALSEN)

카테고리

Sensorion SA (ALSEN)의 P/B 비율
July 2026 기준 P/B 비율 TTM: 1.60
Sensorion SA의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 1.60입니다. 2023년 말 기준 P/B 비율은 1.72였습니다.
Sensorion SA의 P/B 비율 기록 (2011 ~ 2026)
매년 말 P/B 비율
연도 P/B 비율 변화
2026 (TTM) 1.60 -36.00%
2024 2.50 45.20%
2023 1.72 27.66%
2022 1.35 -61.30%
2021 3.49 123.40%
2020 1.56 30.96%
2019 1.19 -63.54%
2018 3.27 -14.29%
2017 3.82 0.09%
2016 3.81 33.08%
2015 2.87 -106.25%
2014 -45.83 271.31%
2013 -12.34 -102.18%
2012 567.35 254.28%
2011 160.14 0.00%
유사 기업 또는 경쟁사의 P/B 비율
회사 P/B 비율 P/B 비율 차이 국가
6.8826 330.16%
DK
6.5189 307.43%
US
2.0637 28.98%
US
4.5808 186.30%
BE
7.7629 385.18%
NL